Bret Stetka, MD; Rohan D'Souza, MD, MRCOG, FCPS, DNB, DGO, DFP; Amarnath Bhide, MD, FRCOG
Hello, I'm Dr. Bret Stetka, Editorial Director at Medscape. Welcome to the F1000 Practice-Changing Minute, where we report commentaries from the Faculty of 1000 on highly rated studies that may change clinical practice. Our commentary today covers the study "A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy," from Rouse and colleagues, published in The New England Journal of Medicine.[1] The Faculty of 1000 Medicine has given this a ranking of Changing Clinical Practice and Must Read with a factor of 8.(...)
The investigators of this trial and the subsequent Cochrane review have unequivocally recommended the antenatal use of magnesium sulfate for fetal neuroprotection in women deemed at a high risk for preterm labor, and this has been endorsed by various other authorities.[5,6] The American College of Obstetricians and Gynecologists in their committee opinion paper[6] have encouraged physicians electing to use magnesium sulfate for the purpose of fetal neuroprotection to develop specific guidelines in regard to inclusion criteria, treatment regimens, concurrent tocolysis, and maternal-fetal monitoring. This should encourage more widespread use of this easily available drug with the primary intention of reducing the risk for neurologic adverse outcomes in this vulnerable group of infants.
Read the rest of the article and watch the video here.
No comments:
Post a Comment